Loading...
Market
Will Lykos Therapeutics complete the additional Phase 3 study for MDMA-assisted therapy for PTSD by December 31, 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Lykos Therapeutics official announcements and clinical trial registries
Story
FDA Rejects MDMA for PTSD Treatment, Requests More Research
Aug 9, 2024, 09:21 PM
The U.S. Food and Drug Administration (FDA) has rejected the application for the use of MDMA-assisted therapy to treat PTSD. The decision marks a setback for the psychedelic space, as the agency has requested an additional Phase 3 study to further investigate the safety and effectiveness of MDMA. Lykos Therapeutics, the company behind the application, will need to conduct further research to address the FDA's concerns.
View original story
Similar markets
Yes • 50%
No • 50%
Approved without restrictions • 25%
Approved with restrictions • 25%
Not approved • 25%
Decision delayed • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved without restrictions • 25%
Approved with restrictions • 25%
Rejected • 25%
Decision delayed • 25%